Compugen Ltd. (NASDAQ: CGEN) reported a net profit of $56.8 million for its fourth quarter of 2025, translating to earnings per share of $0.60. The profit margin was driven largely by a $65 million upfront payment from AstraZeneca for the monetization of a portion of the rilvegostomig royalty stream, which was the single largest revenue driver for the quarter.
Revenue for the quarter rose to $67.3 million, a 67% increase from the $1.5 million earned in Q4 2024. The jump was almost entirely attributable to the AstraZeneca payment; the company also received milestone and licensing income from Gilead for its IL‑18 binding protein program, adding a modest but meaningful contribution to the top line.
Cash and cash equivalents at year‑end climbed to $145.6 million, giving the company a runway that management projects extends into 2029. The non‑dilutive nature of the AstraZeneca deal removes the need for immediate equity financing and provides a stable financial foundation for ongoing pipeline development.
Management highlighted progress in the clinical pipeline, noting the initiation of dosing in the MAIA‑ovarian trial for COM701 and the Phase 1 program for GS‑0321. Dr. Eran Ophir, President and CEO, said the company “delivered important progress in 2025, highlighted by the extension of our cash runway into 2029 through a non‑dilutive monetization agreement with AstraZeneca for rilvegostomig.” He added that the company “continues to execute with discipline” and that the new cash position supports future milestone inflows.
The earnings beat was substantial: EPS of $0.60 surpassed analyst consensus of $0.05, a beat of $0.55 or 1,100%. Revenue of $67.3 million eclipsed the consensus estimate of approximately $2.16 million, a beat of $65.1 million or over 3,000%. The magnitude of the beat reflects the one‑off nature of the AstraZeneca payment and the company’s ability to convert partnership agreements into immediate cash flow.
The market reaction was driven by the strong earnings and revenue beat, the non‑dilutive cash infusion, and the extended runway. Investors viewed the results as a sign of robust financial health and a clear path to fund pipeline milestones without additional capital raises.
The company’s prior quarter results show a net loss of $6.1 million or $0.07 per share in Q3 2025, and the same loss in Q3 2024, underscoring the turnaround achieved in Q4 2025.
The analyst consensus for revenue was far lower than the reported figure, indicating that the market had not fully priced in the impact of the AstraZeneca deal. The large beat on both EPS and revenue signals that the company’s partnership strategy is delivering tangible financial benefits.
The company’s cash position and runway extension provide a buffer against future headwinds in the competitive immuno‑oncology space, while the initiation of new clinical trials positions Compugen for potential future milestone inflows and long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.